Tags

Type your tag names separated by a space and hit enter

Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
Expert Rev Clin Pharmacol 2018; 11(9):889-902ER

Abstract

INTRODUCTION

Mood, anxiety, and substance-use disorders are among the most prevalent psychiatric disorders in the population. Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions. Therefore, new treatments should be explored. Recent studies suggest that serotonergic hallucinogens/psychedelics including ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) have anxiolytic, antidepressive, and antiaddictive effects. Areas Covered: A systematic review of systematic reviews assessing the efficacy, safety, and tolerability of serotonergic hallucinogens/psychedelic was performed using the PubMed data base until 11 April 2018. Systematic reviews with or without meta-analysis were analyzed, but only reviews that described at least one randomized controlled trial (RCT) were included. Expert Commentary: Psilocybin and LSD reduced anxiety and depression in cancer patients and symptoms of alcohol and tobacco dependence, and ayahuasca reduced depression symptoms in treatment-resistant depression. Although the results are promising, several studies were open label, and only few were RCTs, and most had small sample sizes and a short duration. Single or few doses of these drugs seem to be well tolerated, but long-term studies are lacking. New RCTs with bigger samples and longer duration are needed to replicate these findings.

Authors+Show Affiliations

a ICEERS Foundation (International Center for Ethnobotanical Education, Research and Services) , Barcelona , Spain. b Department of Neurosciences and Behavior, Ribeirão Preto Medical School , University of São Paulo , Ribeirão Preto , Brazil. c Translational Medicine , National Institute of Science and Technology , Ribeirão Preto , Brazil.a ICEERS Foundation (International Center for Ethnobotanical Education, Research and Services) , Barcelona , Spain.d Departamento de Psicología Biológica y de la Salud. Facultad de Psicología , Universidad Autónoma de Madrid , Madrid , Spain.b Department of Neurosciences and Behavior, Ribeirão Preto Medical School , University of São Paulo , Ribeirão Preto , Brazil. c Translational Medicine , National Institute of Science and Technology , Ribeirão Preto , Brazil.

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

30102078

Citation

Dos Santos, Rafael G., et al. "Efficacy, Tolerability, and Safety of Serotonergic Psychedelics for the Management of Mood, Anxiety, and Substance-use Disorders: a Systematic Review of Systematic Reviews." Expert Review of Clinical Pharmacology, vol. 11, no. 9, 2018, pp. 889-902.
Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, et al. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Rev Clin Pharmacol. 2018;11(9):889-902.
Dos Santos, R. G., Bouso, J. C., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert Review of Clinical Pharmacology, 11(9), pp. 889-902. doi:10.1080/17512433.2018.1511424.
Dos Santos RG, et al. Efficacy, Tolerability, and Safety of Serotonergic Psychedelics for the Management of Mood, Anxiety, and Substance-use Disorders: a Systematic Review of Systematic Reviews. Expert Rev Clin Pharmacol. 2018;11(9):889-902. PubMed PMID: 30102078.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. AU - Dos Santos,Rafael G, AU - Bouso,José Carlos, AU - Alcázar-Córcoles,Miguel Ángel, AU - Hallak,Jaime E C, Y1 - 2018/08/23/ PY - 2018/8/14/pubmed PY - 2018/9/18/medline PY - 2018/8/14/entrez KW - 5-HT2A receptor KW - anxiety disorders KW - ayahuasca KW - dimethyltryptamine KW - lysergic acid diethylamide KW - mood disorders KW - psilocybin KW - substance-use disorders SP - 889 EP - 902 JF - Expert review of clinical pharmacology JO - Expert Rev Clin Pharmacol VL - 11 IS - 9 N2 - INTRODUCTION: Mood, anxiety, and substance-use disorders are among the most prevalent psychiatric disorders in the population. Although several pharmacological treatments are available, they are not effective for a significant proportion of patients and are associated with several adverse reactions. Therefore, new treatments should be explored. Recent studies suggest that serotonergic hallucinogens/psychedelics including ayahuasca, psilocybin, and lysergic acid diethylamide (LSD) have anxiolytic, antidepressive, and antiaddictive effects. Areas Covered: A systematic review of systematic reviews assessing the efficacy, safety, and tolerability of serotonergic hallucinogens/psychedelic was performed using the PubMed data base until 11 April 2018. Systematic reviews with or without meta-analysis were analyzed, but only reviews that described at least one randomized controlled trial (RCT) were included. Expert Commentary: Psilocybin and LSD reduced anxiety and depression in cancer patients and symptoms of alcohol and tobacco dependence, and ayahuasca reduced depression symptoms in treatment-resistant depression. Although the results are promising, several studies were open label, and only few were RCTs, and most had small sample sizes and a short duration. Single or few doses of these drugs seem to be well tolerated, but long-term studies are lacking. New RCTs with bigger samples and longer duration are needed to replicate these findings. SN - 1751-2441 UR - https://www.unboundmedicine.com/medline/citation/30102078/Efficacy,_tolerability,_and_safety_of_serotonergic_psychedelics_for_the_management_of_mood,_anxiety,_and_substance-use_disorders:_a_systematic_review_of_systematic_reviews L2 - http://www.tandfonline.com/doi/full/10.1080/17512433.2018.1511424 DB - PRIME DP - Unbound Medicine ER -